1. Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354.
Google Scholar | Crossref | Medline | ISI2. Correia-Melo, FS, Argolo, FC, Araújo-de-Freitas, L, et al. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat 2017; 13: 1627–1632.
Google Scholar | Crossref | Medline3. Diazgranados, N, Ibrahim, L, Brutsche, NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment- resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793–802.
Google Scholar | Crossref | Medline4. McCloud, TL, Caddy, C, Jochim, J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev 2015; 9: CD011611.
Google Scholar5. Short, B, Fong, J, Galvez, V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5: 65–78.
Google Scholar | Crossref | Medline6. Wan, LB, Levitch, CF, Perez, AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2015; 76: 247–252.
Google Scholar | Crossref | Medline | ISI7. Włodarczyk, A, Cubała, WJ, Szarmach, J, et al. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. Psychiatr Danub 2019; 31: 530–533.
Google Scholar | Medline8. McAllister-Williams, RH, Arangoc, C, Blierd, P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord 2020; 267: 264–282.
Google Scholar | Crossref | Medline9. Słupski, J, Cubała, WJ, Górska, N, et al. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. Med Hypotheses 2020; 144: 110268.
Google Scholar | Crossref | Medline10. Szarmach, J, Cubała, WJ, Włodarczyk, A, et al. Metabolic risk factors and cardiovascular safety in ketamine use for treatment resistant depression. Neuropsychiatr Dis Treat 2020; 16: 2539–2551.
Google Scholar | Crossref | Medline11. Poon, SH, Sim, K, Baldessarini, RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol 2015; 13: 592–604.
Google Scholar | Crossref | Medline12. Bremner, JD, Krystal, JH, Putnam, FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11: 125–136.
Google Scholar | Crossref | Medline | ISI13. Włodarczyk, A, Cubała, WJ. Safety and tolerability of ketamine use in treatment-resistant bipolar depression patients with regard to central nervous system symptomatology: literature review and analysis. Medicina 2020; 56: 67.
Google Scholar | Crossref14. Trivedi, MH, Corey-Lisle, PK, Guo, Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 2009; 24: 133–138.
Google Scholar | Crossref | Medline | ISI15. Young, T. What exactly is a mood stabilizer? J Psychiatry Neurosci 2004; 29: 87–88.
Google Scholar | Medline16. Fava, M, Freeman, MP, Flynn, M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 2018; 25: 1592–1603.
Google Scholar | Crossref | Medline17. Lapidus, KAB, Levitch, CF, Perez, AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76: 970–976.
Google Scholar | Crossref | Medline | ISI18. Luckenbaugh, DA, Niciu, MJ, Ionescu, DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 2014; 159: 56–61.
Google Scholar | Crossref | Medline | ISI19. Phillips, JL, Norris, S, Talbot, J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 2019; 176: 401–409.
Google Scholar | Crossref | Medline20. Sos, P, Klirova, M, Novak, T, et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013; 34: 287–293.
Google Scholar | Medline | ISI21. Valentine, GW, Mason, GF, Gomez, R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011; 191: 122–127.
Google Scholar | Crossref | Medline | ISI22. Vidal, S, Gex-Fabry, M, Bancila, V, et al. Efficacy and safety of a rapid intravenous injection of ketamine 0.5mg/kg in treatment-resistant major depression: an open 4-Week longitudinal study. J Clin Psychopharmacol 2018; 38: 590–597.
Google Scholar | Crossref | Medline23. Daly, EJ, Trivedi, MH, Janik, A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry 2019; 76: 893–903.
Google Scholar | Crossref | Medline24. Popova, V, Daly, EJ, Trivedi, M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428–438.
Google Scholar | Crossref | Medline25. Schmechtig, A, Lees, J, Perkins, A, et al. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Transl Psychiatry 2013; 3: e334.
Google Scholar | Crossref | Medline26. Aalto, S, Ihalainen, J, Hirvonen, J, et al. Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005; 182: 375–383.
Google Scholar | Crossref | Medline | ISI27. Kegeles, LS, Martinez, D, Kochan, LD, et al. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002; 43: 19–29.
Google Scholar | Crossref | Medline | ISI28. Vernaleken, I, Klomp, M, Moeller, O, et al. Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol 2013; 16: 745–754.
Google Scholar | Crossref | Medline | ISI29. Dwyer, JM, Duman, RS. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 2013; 73: 1189–1198.
Google Scholar | Crossref | Medline | ISI30. Niciu, MJ, Shovestul, BJ, Jaso, BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord 2018; 232: 310–315.
Google Scholar | Crossref | Medline